Skip to content
Home/ Caprisa Clinical Trials: HIV Treatment and Prevention (Softcover Reprint of the Original 1st 2017)
Caprisa Clinical Trials: HIV Treatment and Prevention (Softcover Reprint of the Original 1st 2017)

Caprisa Clinical Trials: HIV Treatment and Prevention (Softcover Reprint of the Original 1st 2017)

No customer reviews yet ISBN 9783319837567

Since its inception 14 years ago, CAPRISA has conducted numerous clinical studies that have influenced international TB-HIV treatment guidelines as well as HIV prevention through innovations in the microbicide and vaccine fields. This book provides a historical account of how each of CAPRISA's high impact studies was created, developed, implemented, analysed and communicated. In doing so, the reader is taken on a journey that provides glimpses into the genesis of research ideas and how this ultimately leads to a range of HIV prevention and treatment studies that have impacted the global response to the HIV and TB epidemics.

Comprised of 5 sections, the book details the following:

  1. HIV epidemic in South Africa and the establishment of a research centre to undertake clinical, epidemiological and laboratory research on HIV.
  2. CAPRISA's clinical trials on HIV and HSV-2 prevention. These studies investigated the impact of tenofovir gel as topical antiretroviral pre-exposure prophylaxis (PrEP), implementation of topical PrEP through family planning clinics, conditional cash incentives for HIV prevention, HIV vaccines, and passive immunisation with broadly neutralising antibodies.
  3. CAPRISA's research on the treatment of HIV and TB co-infection.
  4. A review of the major scientific findings from the CAPRISA studies on acute infection and genital mucosal immunology.
  5. Essential support activities for the conduct of clinical trials, including research laboratories and pharmacies, as well as establishing effective communication and sustainable structures for community engagement to maintain effective and respectful partnerships with participating communities. The book concludes with a chapter about the challenges facing future HIV prevention and treatment trials.

The CAPRISA ClinicalTrials: HIV Treatment and Prevention is a resource for undergraduate and postgraduate students, health care providers, doctors, decision-makers and researchers who are seeking guidance and insights on clinical trials - their creation, conduct and impact.

About the author

Product details

Pub dateApr 29, 2018
ISBN-103319837567
ISBN-139783319837567
LanguageEnglish
Last updated 2026-08-31 23:55
$166.61
In stock soon — order now to reserve your copy
Delivery by Monday, September 14, 2026
Qty
Sign in to Add to Saved list
Free delivery on orders over $35.
15-day returns. Any reason.
Secure checkout. We never store card details.

Readers who bought this also bought

More from Preventive Medicine
See all
Health Promotion and Health Services: Management for Change
Johnson, Anne
$89.50
Epidemic Streets: Infectious Diseases and the Rise of Preventive Medicine, 1856-1900
Hardy, Anne
$307.53
Mayo Clinic Preventive Medicine and Public Health Board Review
Varkey MD Mph Mhpe, Prathibha
$164.89
Prevention vs. Treatment: What's the Right Balance?
Everyone knows the old adage, "an ounce of prevention is worth a pound of cure," but we seem not to live by it. In the Western world's health care it is commonly observed that prevention is underfunded while treatment attracts greater overall priority. This book explores this observation by examining the actual spending on prevention, the history of health policies and structural features that affect prevention's apparent relative lack of emphasis, the values that may justify priority for treatment or for prevention, and the religious and cultural traditions that have shaped the moral relationship between these two types of care. <p/>Economists, scholars of public health and preventive medicine, philosophers, lawyers, and religious ethicists contribute specific sophisticated discussions. Their descriptions and claims lean in various directions and are often surprising. For example, the imbalance between prevention and treatment may not be as great as is often thought, and we may be spending excessively on many preventive measures just as we do on treatments compelled by the felt demands of rescue. A standard practice in health economics that disadvantages prevention, "discounting" the value of future lives, may rest on weak empirical and moral grounds. And it is an "apocalyptic" religious tradition (Seventh-day Adventism) whose members have put some of the strongest and most effective priority on long-term prevention. <p/>Prevention vs. Treatment is distinctive in carefully clarifying the nature of the empirical and moral debates about the proper balance of prevention and treatment&#x3b; the book pursues those debates from a wide range of perspectives, many not often heard from in health policy.<br>
$103.45
Quantitative Evaluation of HIV Prevention Programs
Available
$85.77
New Vaccines and Chemotherapy (1988)
Viral Vaccines Joseph L. Melnick As with history in general, the history of vaccines needs to be reexamined and updated. My task is to look back to see what has been successful and to look forward to see what remains to be accomplished in the prevention of viral diseases by vaccines. Also, I shall refer to the pertinent material discussed at two recent conferences of the Institute of Medicine, National Academy of Sciences, on virus vaccines under development and their target populations in the United States (1985b) and in developing countries (1986). These reports, plus a third on Vaccine Supply and Innovation (1985a), should be required reading for all those in both the public and the private sector who have a responsibility or interest in vaccines for the prevention of human disease. It has been through the development and use of vaccines that many viral diseases have been brought under control. The vaccines consist either of infectious living attenu- ated viruses or of noninfectious killed viruses or subviral antigens. When we look at the record, it is the live vaccines that have given the great successes in controlling diseases around the world. Examples are smallpox, yellow fever, poliomyelitis, measles, mumps, and rubella.
$177.01